Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0LM2K
|
||||
| Former ID |
DNC009965
|
||||
| Drug Name |
2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H16O4S
|
||||
| Canonical SMILES |
C1=CC=C(C=C1)C2=CC=C(C=C2)CCS(=O)(=O)CC(=O)O
|
||||
| InChI |
1S/C16H16O4S/c17-16(18)12-21(19,20)11-10-13-6-8-15(9-7-13)14-4-2-1-3-5-14/h1-9H,10-12H2,(H,17,18)
|
||||
| InChIKey |
PPYPHJNYICUMPA-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Collagenase 3 | Target Info | Inhibitor | [1] | |
| MMP-12 | Target Info | Inhibitor | [1] | ||
| NetPath Pathway | IL1 Signaling PathwayNetPath_13:IL1 Signaling Pathway | ||||
| IL5 Signaling Pathway | |||||
| PANTHER Pathway | Alzheimer disease-presenilin pathway | ||||
| Plasminogen activating cascade | |||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signalingupa_upar_pathway:Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Assembly of collagen fibrils and other multimeric structuresR-HSA-1442490:Collagen degradation | |||||
| WikiPathways | Endochondral Ossification | ||||
| Activation of Matrix Metalloproteinases | |||||
| Oncostatin M Signaling Pathway | |||||
| AGE/RAGE pathway | |||||
| Matrix MetalloproteinasesWP366:TGF beta Signaling Pathway | |||||
| Degradation of collagen | |||||
| Matrix Metalloproteinases | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. Epub 2009 Aug 6.The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.